Inhibition of the Mammalian Target of Rapamycin and the Induction of Cell Cycle Arrest in Mantle Cell Lymphoma Cells

Overview

Journal Haematologica

Specialty Hematology

Date 2005 Oct 13

PMID 16219581

Citations 22

Authors

Susanne Hipp

Ingo Ringshausen

Madlene Oelsner

Christian Bogner

Christian Peschel

Thomas Decker

Affiliations

Soon will be listed here.

Abstract

Mammalian target of rapamycin (mTOR) inhibitors represent a new class of potential anticancer agents. The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged. This finding was confirmed in cells from a MCL patient.

Citing Articles

The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects.

Karatrasoglou E, Dimou M, Piperidou A, Lakiotaki E, Korkolopoulou P, Vassilakopoulos T Int J Mol Sci. 2023; 24(18).

PMID: 37762410 PMC: 10531792. DOI: 10.3390/ijms241814110.

Targeting autophagy in lymphomas: a double-edged sword?.

Zhang H Int J Hematol. 2018; 107(5):502-512.

PMID: 29380180 DOI: 10.1007/s12185-018-2414-6.

Targeting mTOR for the treatment of B cell malignancies.

Lee J, Vo T, Fruman D Br J Clin Pharmacol. 2016; 82(5):1213-1228.

PMID: 26805380 PMC: 5061788. DOI: 10.1111/bcp.12888.

mTORC signaling in hematopoiesis.

Wang X, Chu Y, Wang W, Yuan W Int J Hematol. 2016; 103(5):510-8.

PMID: 26791377 DOI: 10.1007/s12185-016-1944-z.

Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.

Xie R, He W, Shen M, Shou X, Wang Y, Bao W J Neurooncol. 2015; 125(1):79-89.

PMID: 26297046 DOI: 10.1007/s11060-015-1895-x.